ProQR Therapeutics N.V 6-K/A, filed Dec 12, 2024
ProQR Therapeutics N.V. (PRQR)
About this 6-K/A
ProQR Therapeutics N.V filed this 6-K/A on December 12, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of December 2024
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
This Report on Form 6-K/A (this “Report”) amends the Report on Form 6-K filed by ProQR Therapeutics N.V. (“ProQR”) with the U.S. Securities and Exchange Commission on November 7, 2024 (the “Original Form 6-K”) solely to incorporate by reference the information contained herein and Exhibits 99.1 and 99.2 attached hereto into the registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, and File No. 333-263166) of ProQR, as indicated in the section “Incorporation by Reference.”
Except as set forth herein, this Report speaks as of the original filing date of the Original Form 6-K and does not amend, update or restate any information set forth in the Original Form 6-K or reflect any events that occurred subsequent to the original filing date of the Original Form 6-K.
INCORPORATION BY REFERENCE
This Report and the exhibits hereto, including any amendment and report filed for the purpose of updating such documents, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, and File No. 333-263166) of ProQR and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROQR THERAPEUTICS N.V. | ||
| Date: December 12, 2024 | By: | /s/ René Beukema |
| René Beukema | ||
| Chief Corporate Development Officer and General Counsel | ||
INDEX TO EXHIBITS
*Previously filed.